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Cyclic AMP regulates the HERG K+ channel by dual pathways
Jie Cui*, Yonathan Melman*, Eugen Palma*, Glenn I. Fishman†
and Thomas V. McDonald*
Lethal cardiac arrhythmias are a hallmark of the
hereditary Long QT syndrome (LQTS), a disease
produced by mutations of cardiac ion channels [1].
Often these arrhythmias are stress-induced, suggesting
a relationship between β-adrenergic activation of
adenylate cyclase and cAMP-dependent alteration of
one or more of the ion channels involved in LQTS.
Second messengers modulate ion channel activity
either by direct interaction or through intermediary
kinases and phosphatases. Here we show that the
second messenger cAMP regulates the K+ channel
mutated in the LQT2 form of LQTS, HERG [2], both
directly and indirectly. Activation of cAMP-dependent
protein kinase (PKA) causes phosphorylation of HERG
accompanied by a rapid reduction in current amplitude,
acceleration of voltage-dependent deactivation, and
depolarizing shift in voltage-dependent activation. In a
parallel pathway, cAMP directly binds to the HERG
protein with the opposing effect of a hyperpolarizing
shift in voltage-dependent activation. The summation of
cAMP-mediated effects is a net diminution of the
effective current, but when HERG is complexed with
with the K+ channel accessory proteins MiRP1 or minK,
the stimulatory effects of cAMP are favored. These
findings provide a direct link between stress and
arrhythmia by a unique mechanism where a single
second messenger exerts complex regulation of an ion
channel via two distinct pathways.
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Results and discussion
Although the rapidly activating delayed rectifier (IKr) and it
pore-forming subunit HERG have been thought to be
insensitive to cAMP-dependent regulation [2,3], recent
reports have shown PKA-mediated effects on HERG [4,5].
Moreover, sequence homology of the carboxyl terminus of
HERG with cyclic nucleotide binding proteins suggests
that cAMP might regulate IKr independent of its activation
of PKA. Thus, we examined the effects of cAMP on
HERG K+ channels in a heterologous mammalian expres-
sion system. Voltage-activated potassium currents typical
of HERG/IKr were measured in CHO cells expressing
cloned HERG under whole-cell patch clamp before and
after addition of the membrane-permeable cAMP analog,
8-chlorophenylthio-adenosine 3:5′-cyclic monophosphate
(CPT-cAMP). A consistent decrease in K+ current ampli-
tude occurred within 3 minutes after introduction of
500 µM CPT-cAMP (Figure 1a,c). With the current reduc-
tion, we observed acceleration in the kinetics of voltage-
dependent deactivation. Both effects occurred within the
first 3 minutes of CPT-cAMP administration and persisted
for the duration of the experiments. CPT-cAMP reduced
HERG current by about 40% at all potentials (Figure 1b).
Both the fast and slow time constants of deactivation were
accelerated with the greatest effects at more positive
potentials (Figure 1d). The relative contribution of the fast
time constant was increased at all potentials (Figure 1d,
inset). When the data were independently normalized to
unity before and after cAMP, no significant change in
voltage-dependence of activation or inactivation due to
cAMP was seen (Figure 1b, insets). Voltage curves were
fitted by a Boltzman function, I = 1/(1 + exp[(Vh–V)/k]),
where I is the relative tail current amplitude, V is the
test potential, Vh is the test potential producing half-
maximal current, and k is the slope factor. Analysis
revealed a small depolarizing shift in activation after
cAMP addition (Vh(baseline) = –5.1 ± 0.18 mV, k = 11.1
Vh(cAMP) = –4.0 ± 0.26 mV, k = 11.1). cAMP therefore
decreases effective HERG activity through current inhibi-
tion and accelerated deactivation kinetics with minimal
alteration of voltage-dependent activation.
To assess whether cAMP was acting on HERG through
PKA, the specific peptide inhibitor PKI was included in
the patch pipette and cells were studied after pre-incu-
bation with membrane-permeable myristolated PKI.
PKI abolished the cAMP-mediated changes in deactiva-
tion kinetics and prevented nearly all of the cAMP-
mediated current reduction (Figure 2a). While cAMP
alone caused a modest positive shift in voltage-depen-
dence of activation in HERG (+1.1 mV), in the presence
of PKI, cAMP produced a leftward shift in both
current–voltage and activation curves of 7.5 ± 0.3 mV
negative from baseline (Vh(baseline) = –3.1 ± 0.22 mV,
k = 10.8 Vh(cAMP) = –11.6 ± 0.37 mV, k = 12.0). PKI also
prevented the cAMP-dependent acceleration of deactiva-
tion previously seen (data not shown). No significant
changes in current density or deactivation kinetics were
elicited by cGMP (data not shown), confirming the cAMP-
specificity of our observed effects. 
We identified four potential consensus sequence sites for
phosphorylation by PKA, (Ser280, Ser887, Thr892, and
Ser1134), all predicted to be at intracellular locations. We
mutagenized these amino acids to alanines in various com-
binations to produce a panel of non-PKA phosphorylatable
mutants (Figure 3a). Immunoprecipitation of HERG via a
carboxy-terminal Myc epitope tag revealed that the
channel protein could be 32P-phosphorylated in vivo in a
cAMP-dependent fashion (Figure 3b). HERG protein
could also be phosphorylated in vitro with the purified cat-
alytic subunit of PKA and [γ-32P]ATP (Figure 3c). In con-
trast to the wild-type channel protein, HERG∆P1–4, a
mutant with all four PKA sites removed, was not 32P-phos-
phorylated in a cAMP-dependent manner in vivo or
in vitro. The specific PKA-dependent phosphorylation of
HERG∆P1–4 was <95% compared with wild-type HERG.
In vitro assays of mutants with single PKA sites revealed
that all were targets for PKA-dependent phosphorylation
(Figure 3d). The relative contribution to the total PKA-
dependent phosphorylation by each was: site 1, 61 ± 4%;
sites 2,3, 30 ± 3%; site 4, 6.1 ± 1%. 
Whole cell patch clamp recordings from cells expressing
the PKA mutants all demonstrated recognizable IKr-type
current, but responses to cAMP were different from those
of wild-type HERG. At baseline the voltage-activation
curve for HERG∆P1–4 was left-shifted compared to wild-
type HERG (Vh∆1–4 = –15.9 ± 0.6 mV, k = 7.8). CPT-
cAMP shifted the voltage-dependent activation of
HERG∆P1–4 further negative (Vh = –22.9 ± 0.25 mV,
k = 9.2; Figure 2b). Current amplitude after CPT-cAMP
was reduced by 9% compared to 40% seen with wild-type
HERG. cAMP effects on deactivation kinetics were nearly
abolished in HERG∆P1–4 (data not shown). The cAMP-
mediated effects in individual site mutants were interme-
diate, indicating that each of the phosphorylation sites
contributes to the PKA-dependent effects (Figure 3c,d). 
HERG channel subunits are thought to exist in hetero-
multimeric complexes with one or more proteins to form
cardiac IKr [6,7]. To examine the effects of cAMP on
human cardiac IKr we co-expressed HERG or HERG∆1–4
with either minK or hMiRP1. In cells expressing
HERG–minK or HERG–hMiRP1, CPT-cAMP produced
a leftward shift in voltage-activation and current ampli-
tude inhibition was reduced (with hMiRP1) or absent
(with minK) (Figure 2c–f). The Vh for HERG–minK
shifted from 4.0 ± 0.56 mV to –4.5 ± 1.02 mV (baseline
k = 10.1, cAMP k = 15.7) after cAMP, whereas the values
672 Current Biology Vol 10 No 11
1.0
0.6
0.3
0
4
2
0
0.5
1.0
0.5
(a) (b)
(c) (d)
(e)
1.0
0.5
1.0
0.5
1.0
0.5
I/Imax
I/Imax
I/Imax
–40 0 40
–40 0 40
Test potential
(mV)
Test potential
(mV)
Test potential
(mV)
–40–80 –20 200 40
–4
0
–8
0
–6
0
–1
00
–40–80 –60–100–40–80 –60–100
–40 0 40
Test potential (mV)
Test potential (mV) Test potential (mV)
Depolarising potential (mV)
I/
I m
ax
   Current Biology   
Control
Control
Control
Time
Time
TimeTime
Current
Current
Current
Time
Current
Time
CPT-cAMP
CPT-cAMP
CPT-cAMP
P
ot
en
tia
l
P
ot
en
tia
l
–40
–70
–70
20
100
pA
100
pA
1 sec
1 sec
t fast
(sec)
t slow
(sec)
t
fa
st
/t
ot
al(f)
Figure 1
cAMP-mediated effects on HERG K+ currents expressed in CHO cells.
(a,b) Current tracings (a) before and (b) 3 min after treatment with
500 µM CPT-cAMP. Currents were elicited by 4 sec depolarizing steps
to various levels followed by a repolarizing step to –40 mV (starting at
arrowheads). Scale bars, 100 pA and 1 sec. (c) Current–voltage (I–V)
relation curve (relative current amplitude, I/Imax, during depolarizing
steps plotted against the step potential, Imax = maximal current before
cAMP) before and after CPT-cAMP (means ± SEM n = 42). Inset, data
were normalized to unity before and after cAMP, showing that there is
no shift in the current–voltage relation. (d) Voltage-dependent activation
curves plotted from peak tail currents during a repolarizing step to
–40 mV after depolarizing to various voltages as in (a). Inset, the same
data normalized to the maximum current in the same curve.
(e) Repolarizing tail currents before and after treatment with CPT-
cAMP, showing current reduction and acceleration of deactivation.
Voltage clamp protocol, as shown in the central diagram: holding
potential –70 mV, depolarizing step to 20 mV for 1.7 sec (arrows),
repolarizing steps for 6 sec (arrowheads). (f) Summary of deactivation
kinetic analysis shows acceleration of both fast (left graph) and slow
(right graph) time constants of deactivation in a voltage dependent
fashion. Inset, relative contribution of fast time constant vs. voltage.
White circles, control; black circles, after treatment with CPT-cAMP. 
for HERG–hMiRP1 were –3.0 ± 0.4 mV to –7.5 ± 0.2 mV,
respectively (baseline k = 11.7, cAMP k = 10.2). cAMP also
generated a greater hyperpolarizing shift in voltage-
dependent activation for HERG∆1–4 when co-expressed
with either minK (Vh = –2.4 ± 0.33 mV at baseline to
–21.0 ± 0.33 mV after cAMP) or hMiRP1 (Vh = –13.7
± 0.8 mV at baseline to –27.2 ± 0.3 mV after cAMP). Thus,
when HERG is in an heteromeric complex, as in cardiac
myocytes, the PKA-independent effects of cAMP on IKr
appear to predominate over the PKA-mediated effects.
To investigate a possible direct cAMP–channel interaction,
we performed in vitro binding assays of labeled cyclic
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Figure 2
Inhibition of PKA suppresses cAMP-mediated effects on HERG and
unmasks voltage activation shift. (a) Voltage-activation (and
current–voltage (I–V) curves, insets) curves of HERG currents from
cells internally dialyzed with PKI peptide before and after treatment with
CPT-cAMP; means ± SEM; n = 22. (b) Normalized voltage-activation
curves from HERG∆P1–4 before and after CPT-cAMP. The inset
shows summary I–V curves from the same cells; means ± SEM, n = 18.
(c,d) Voltage-activation and summary I–V curves for (c) HERG–hMiRP1
and (d) HERG∆1–4–hMiRP1 before and after CPT-cAMP.
(e,f) Voltage-activation and summary I–V curves for (e) HERG–minK
and (f) HERG∆1–4–minK before and after CPT-cAMP. White circles,
control; black circles, after treatment with CPT-cAMP.
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Figure 3
Mutation of PKA phosphorylation sites and direct cAMP-HERG
binding. (a) Representation of the PKA-phosphorylation site mutants
constructed. (b) In vivo phosphorylation of HERG, showing that wild-
type HERG but not the HERG∆P1–4 mutant was 32P-labeled in a
cAMP-dependent fashion. (c) In vitro phosphorylation of HERG by
PKA, (top) showing an anti-Myc western blot of wild-type HERG and
HERG∆P1–4 and (bottom) an autoradiogram of the same blot
showing >95% reduction in specific PKA-mediated phosphorylation of
HERG∆P1–4. (d) Relative amount of in vitro phosphorylation of each
PKA consensus site in HERG. (e) Summary data for cAMP-dependent
current amplitude reduction for HERG and each phosphorylation site
mutant. Bars represent the fractional reduction of peak tail currents
after addition of CPT-cAMP (± SEM). (f) Data for cAMP-dependent
changes in voltage-dependent activation shift for HERG and each
phosphorylation site mutant. Bars represent change in voltage
producing half-maximal tail current activation (Vh ± SEM). (g) 3H-cAMP
binding competition assay of immunoprecipitated HERG. Data are
pooled from six determinations and normalized for comparison. Inset,
binding of 3H-cAMP or 3H-cGMP to immunoprecipitated HERG in the
absence (black bars) or presence (gray bars) of excess unlabeled
cyclic nucleotide (means ± SEM; n = 4). (h) Direct photoaffinity
labeling of HERG with 8-azido-[γ-32P]cAMP. The signal increases in a
dose-dependent fashion and is blocked by unlabeled cAMP, with
complete inhibition above 200 µM. 500 µM unlabeled cGMP partially
inhibits 8-azido-[γ-32P]cAMP binding. HERG∆P1–4 is also labeled by
8-azido-[γ-32P]cAMP.
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nucleotides to the HERG protein. Immunoprecipitated
HERG–Myc was used to determine direct nucleotide inter-
action with either 8-3H-cAMP or the photo-reactive 8-azido-
[γ-32P]-cAMP in the presence or absence of excess
unlabeled cAMP. Binding competition curves of unlabeled
cAMP with 3H-labeled nucleotide indicate a relatively low,
but specific, affinity of the channel for cAMP (40.7 ±7.2 µM,
n = 5 determinations; Figure 3g). The calculated specific
3H-cAMP-binding capacity of HERG suggest a stoichio-
metry of four molecules per channel (1.3 ± 0.24 moles
HERG per mole channel subunit). These results are com-
parable to published binding and stoichiometry data for
cyclic nucleotide-gated channels (CNGC) [8,9]. Gel analysis
showed specific photoaffinity labeling of HERG by 8-azido-
[γ-32P]cAMP that could be competitively blocked with
excess unlabeled cAMP (above 100 µM; Figure 3h).
Although no specific binding of cGMP was observed in
either assay, excess unlabeled cGMP could partially inhibit
cAMP binding (Figure 3g, inset). 
Taken together, our results show that stimuli that elevate
cAMP exert multiple and complex effects on HERG func-
tion though separate signaling pathways (see model,
Figure 4). PKA directly phosphorylates HERG, producing
an inhibition of current at all voltages, accelerated deacti-
vation and a rightward shift in voltage dependence of acti-
vation. By shifting the voltage-gated activation to more
depolarized potentials, PKA-dependent phosphorylation
of HERG renders the channel less likely to open during
action-potential voltages. PKA-dependent acceleration of
deactivation kinetics would reduce the unique control
HERG/IKr has on the rapid repolarizing phase of the
cardiac myocyte action potential. Thus, the PKA-depen-
dent effects combine to decrease effective HERG/IKr
activity. Simultaneously, cAMP directly binds to the
HERG protein and shifts the voltage-dependence of acti-
vation to depolarized potentials. Although this direct
effect counterbalances the PKA-dependent shift in
voltage activation, the current inhibition and accelerated
deactivation remain unopposed, and the net effect is
diminution of HERG current. When HERG is complexed
with minK or MiRP, however, the relative contribution of
direct cAMP effects on IKr is accentuated.
Distinct channel mutations are associated with different
responses to stress and exercise. During adrenergic stimu-
lation in individuals with LQT1, the main cAMP-respon-
sive repolarizing current, IKs, is reduced or absent. Our
data suggest that, for LQT1, stress-induced cAMP may
also reduce the only remaining delayed rectifier current,
IKr, thus further impairing repolarization. Our results cor-
relate well with clinical data and provide a mechanistic
link in the pathophysiology of stress-induced arrhythmia
in LQTS. If the PKA-dependent pathway could be selec-
tively inhibited while cAMP was still allowed to rise, then
adrenergic stimulation might have a beneficial effect on
myocyte membrane repolarization. Thus, this demonstra-
tion of cAMP’s dual pathways of HERG regulation may
provide a basis for a more genotype-specific therapy.
Supplementary material
Supplementary material including additional discussion and method-
ological details is available at http://current-biology.com/supmat/sup-
matin.htm.
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Figure 4
A model illustrating the complexity of cAMP regulation of HERG K+
channel protein using two distinct pathways. Stress elevates
catecholamines that stimulate β-adrenergic (βAR) receptors to activate,
via G-protein (Gs), adenyl cyclase (AC). The resulting increase in cAMP
produces regulation of HERG. NBD, nucleotide-binding domain.
   Current Biology   
StimulatoryNBD
cAMP
PKA
βAR
Gs AC
CatecholamineHERG
Inhibition
P
P
PP
